One of the biggest factors propelling the demand for organ-on-chip is the increasing number of investments being made in research by the governments of several countries all around the world. For instance, the National Center for Advancing Translational Sciences (NCATS) gave a research grant worth $2 million to Emulate Inc. in July 2017, in order to allow the company to leverage its human Brain-Chip system and create a fully automated research platform for conducting experiments on the International Space Station.

The other major factor responsible for the rising demand for organ-on-chip is the increasing need for alternatives to the conventionally used animal models in research activities. In many countries, doctors and medical researchers are raising concerns over the scientific validity and translatability of the animal alternatives of human diseases and this is massively boosting the demand for alternative drug and diseases research techniques. The increasing initiatives being taken by the pharmaceutical companies for promoting the adoption of organ-on-chip models are expected to further push the demand for organ-on-chip based research methods in future.

The major trends currently being witnessed in the organ-on-chip market are the rising number of product launches and increasing collaborations amongst the leading organ-on-chip using laboratories and organizations across the world. For instance, in October 2017, InSphero AG started a collaboration with Charles River Laboratories International, Inc. (Charles River). With this collaboration, Charles River intends to award InSphero AG the license its collection of patient-derived xenograft (PDX) tumors. In addition to this, Charles River also plans to leverage the proprietary 3D cell culture technology of InSphero Ag in order to extend its pre-clinical services.

Geographically, the Asia-Pacific (APAC) region is predicted to observe huge growth in the usage of organ-on-chip products during the forecast period. This is primarily ascribed to the rising healthcare expenditure, soaring government initiatives and investments for healthcare research and development (R&D) activities, and the surging adoption of advanced healthcare and research technologies in the region. For instance, several government organizations in China such as the Chinese Academy of Sciences are increasingly adopting organ-on-chip products for biological analysis in various applications.

Hence, it can be concluded that owing to the surging investments in advanced technologies and research methods in the healthcare industry and the shifting focus toward alternative testing models in drug discovery and disease research processes, the demand for organ-on-chips will increase considerably in the coming years.